Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

(2013) Sylvain Thépot et al.   AMERICAN JOURNAL OF HEMATOLOGY

Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)

(2013) Bernard Tawfik et al.   ANNALS OF HEMATOLOGY

Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure

(2013) Vu H. Duong et al.   Clinical Lymphoma Myeloma & Leukemia

CD30 expression in peripheral T-cell lymphomas

(2013) E. Sabattini et al.   HAEMATOLOGICA

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

(2013) S. D. Gore et al.   HAEMATOLOGICA

Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy

(2013) Bhavana Bhatnagar et al.   LEUKEMIA & LYMPHOMA

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

(2012) Ellen K. Ritchie et al.   LEUKEMIA & LYMPHOMA

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

(2011) Lewis R. Silverman et al.   CANCER

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

(2011) M. Lubbert et al.   HAEMATOLOGICA

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

(2011) Thomas Prébet et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

(2011) Michael Lübbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

(2010) Elias Jabbour et al.   CANCER

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

(2010) Paul W. Hollenbach et al.   PLoS One

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

(2009) David P. Steensma et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

(2009) Amanda F. Cashen et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines

(2008) T. Qin et al.   BLOOD

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

(2008) Gautam Borthakur et al.   LEUKEMIA & LYMPHOMA